[Nivolumab (adenocarcinoma of the stomach, the gastro-oesophageal junction or the oesophagus) - 2nd Addendum to Commission A21-146]
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018004093
German
Original Title:
Nivolumab (Adenokarzinom des Magens, des gastrooesophagealen Uebergangs oder des Oesophagus)
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/g22-13.html
Year Published:
2022
URL for published report:
https://www.iqwig.de/download/g22-13_nivolumab_addendum-zum-auftrag-a21-146_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Adenocarcinoma
- Esophagogastric Junction
- Esophageal Neoplasms
- Stomach Neoplasms
- Nivolumab
- Antineoplastic Agents, Immunological
- Antibodies, Monoclonal, Humanized
- Immune Checkpoint Inhibitors
Keywords
- Nivolumab
- Adenocarcinoma
- Health Care Costs
- Epidemiology
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.